<DOC>
	<DOCNO>NCT01383746</DOCNO>
	<brief_summary>Cholangiocarcinoma ( CCK ) rare tumor ( 2000 new cases/year France ) poor prognosis ( overall survival &lt; 3 % 5 year ) . Less 20 % patient may benefit curative surgical resection patient medical treatment palliative treatment palliative chemotherapy . It standard first-line chemotherapy validate unresectable CCK , best objective response rate ( OR ) overall survival ( OS ) observe gemcitabine platinum association ( OR 24 36 % OS 9.5 15.4 month ) . In case tumor progression ater first line therapy , treatment currently validate . RADIOEMBOLIZATION ( RE ) new , transarterial approach radiation therapy use 90 Yttrium microspheres . In patient unresectable CCK , first pilot study show interesting result rate OR 45 90 % median OS 14.9 mot acceptable safety . Study Hypothesis : RE could help achieve tumor stabilization patient intra-hepatic CCK tumor progression first-line therapy .</brief_summary>
	<brief_title>Second-line Therapy Unresectable Cholangiocarcinoma RADIOEMBOLIZATION</brief_title>
	<detailed_description>Extended description protocol , include information already contain field , comparison study . It pilot study include 20 patient unresectable intra-hepatic CCK tumor progression first-line therapy . Description protocol : 1 . Information sign CONSENTMENT 2 . Preparatory phase : pre-treatment mesenteric angiography technetium-99m macroaggregated albumin scan perform assess gastrointestinal flow lung shunt . 3 . Therapeutic phase : intra-arterial administration resin-based microspheres ( SIRSPHERES , SIRTEX ) . The RE perform 2 session , especially liver disease bi-lobar . 4 . Follow J15 , M1 , M2 , M4 M6 : clinical examination image evaluation ( scan /or MRI )</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Cholestasis , Intrahepatic</mesh_term>
	<criteria>Unresectable intrahepatic CCK histologically proven Tumor progression document imaging evaluation ( CT MRI ) accord RECIST criterion version 1.1 firstline therapy Performance status &lt; 2 ; 4 ) Bilirubin &lt; 36 micromol/l age &gt; 18 year Extrahepatic metastasis Uncontrolled biliary obstruction Contraindications RE .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Cholangiocarcinoma</keyword>
	<keyword>RADIOEMBOLIZATION</keyword>
	<keyword>tumor response</keyword>
	<keyword>progression-free survival</keyword>
	<keyword>safety</keyword>
	<keyword>second-line therapy</keyword>
</DOC>